VYLUMA ANNOUNCES POSITIVE RESULTS FROM SECOND STAGE OF PHASE III CHAMP STUDY OF NVK002 FOR THE TREATMENT OF MYOPIA IN CHILDREN
Vyluma announced today positive top-line results from the second stage of its Phase III CHAMP (Childhood Atropine for Myopia Progression) clinical study of its lead compound…
Nevakar Injectables Announces FDA Approval of Cyclophosphamide RTD Solution
-- Ready-to-dilute, multi-dose vials reduce compounding time and waste -- Bridgewater, NJ, July 3, 2023 – Nevakar Injectables Inc. (“Nevakar”), a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care...
VYLUMA ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR NVK002, ITS NOVEL INVESTIGATIONAL TREATMENT FOR PEDIATRIC MYOPIA
Bridgewater, NJ – June 6, 2023 – Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets for the treatment of refractive errors, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application...
VYLUMA TO PRESENT AT THE 41ST ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Vyluma, a biopharmaceutical company developing multiple assets for the treatment of refractive errors, today announced it will participate in the 41st annual J.P. Morgan Healthcare Conference, taking place January 9-12, 2023 in San Francisco, Calif.
VYLUMA ANNOUNCES POSITIVE RESULTS FROM PHASE 3 CHAMP STUDY OF NVK002 FOR TREATMENT OF MYOPIA PROGRESSION IN CHILDREN
Preliminary data from landmark, three-year, international study demonstrate safety and efficacy of NVK002 as a potential treatment for the progression of myopia in children Bridgewater, NJ – October 27, 2022 – Vyluma, Inc (“Vyluma”), a biopharmaceutical...
VYLUMA COMPLETES LAST PATIENT VISIT FOR PRIMARY ANALYSIS OF PIVOTAL PHASE III CHAMP STUDY EVALUATING NVK002 FOR THE TREATMENT OF MYOPIA PROGRESSION IN CHILDREN
Multi-center, international clinical study designed to assess the safety and efficacy of novel investigational low-dose atropine eye drops in children 3-17 years old with myopia
VYLUMA AND LABORATOIRES THÉA ENTER INTO LICENSING AGREEMENT FOR THE REGISTRATION AND COMMERCIALIZATION OF NVK002 IN CANADA, MEXICO, AND SELECT SOUTH AMERICAN COUNTRIES
Bridgewater, NJ, USA, June 14, 2022 – Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets in the ophthalmic space for the treatment of refractive errors, and Laboratoires Théa (“Théa”) announced that they have recently entered into an...
NEVAKAR INJECTABLES SELLS SIX DEVELOPMENT-STAGE, READY-TO-USE INJECTABLE PRODUCT CANDIDATES TO ENDO VENTURES LIMITED
Bridgewater, NJ, May 2, 2022 – Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings. Nevakar announced...
NEVAKAR INJECTABLES RECEIVES U.S. FDA APPROVAL OF READY-TO-USE EPHEDRINE INJECTION IN A PREFILLED SYRINGE
Bridgewater, NJ, USA, April 28, 2022 – Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings, and announced...
Nevakar Injectables Announces the Launch of Ready-to-Use Ephedrine Injection Vials
Bridgewater, NJ, USA, March 28, 2022 – Nevakar Injectables Inc., a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings, announced today the launch of its ready-to-use Ephedrine Sulfate...